Noticias y Actividades de Garuda Therapeutics
Ejecutivos
Ver el organigrama con sus 19 ejecutivos principales
Biografías más buscadas en Garuda Therapeutics
- Avanish Vellanki, President and Chief Executive Officer and Direct...
- Adam Craig, Independent Director
- Laurence Reid, Director
Recientes movimientos de ejecutivos en Garuda Therapeutics
- Avanish Vellanki, se ha incorporado a la empresa como President and Chief Executive Officer and Director (noticia publicada el 4 de marzo de 2025).
- Adam Craig que ha sido Interim Chief Executive Officer, pasa a ser Independent Director (noticia publicada el 4 de marzo de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Garuda Therapeutics.
Biotecnología
Garuda Therapeutics tiene 2.347 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Garuda Therapeutics
- Garuda Therapeutics Announces the Appointment of Avanish Vellanki as President and Chief Executive Officer
- Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies
- Garuda Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
- Garuda Therapeutics Announces the Appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer
- Be The Match BioTherapies® To Provide Robust Cell Therapy Infrastructure to Support Garuda Therapeutics’ Potentially Ground-Breaking Off-The-Shelf Cell Therapies
- Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
- Garuda Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
- Garuda Therapeutics Announces Appointment of David DiGiusto, Ph.D., as Chief Technology Officer
- Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer
- View more press releases Close
Redes sociales sobre Garuda Therapeutics
- Garuda Therapeutics en Wikipedia, Google News y Yahoo Finance
- Garuda Therapeutics en LinkedIn, Twitter y YouTube
